Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
- 5 February 2001
- journal article
- clinical trial
- Published by Elsevier BV in Vaccine
- Vol. 19 (13-14), 1732-1737
- https://doi.org/10.1016/s0264-410x(00)00395-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Risk of Influenza A (H5N1) Infection among Health Care Workers Exposed to Patients with Influenza A (H5N1), Hong KongThe Journal of Infectious Diseases, 2000
- Antibody Response in Individuals Infected with Avian Influenza A (H5N1) Viruses and Detection of Anti‐H5 Antibody among Household and Social ContactsThe Journal of Infectious Diseases, 1999
- Case‐Control Study of Risk Factors for Avian Influenza A (H5N1) Disease, Hong Kong, 1997The Journal of Infectious Diseases, 1999
- Characterization of the Surface Proteins of Influenza A (H5N1) Viruses Isolated from Humans in 1997–1998Virology, 1999
- Human influenza A H5N1 virus related to a highly pathogenic avian influenza virusThe Lancet, 1998
- Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virusThe Lancet, 1998
- Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory IllnessScience, 1998
- Recombinant Baculovirus Influenza A Hemagglutinin Vaccines Are Well Tolerated and Immunogenic in Healthy AdultsThe Journal of Infectious Diseases, 1996
- Evaluation of a Recombinant Hemagglutinin Expressed in Insect Cells as an Influenza Vaccine in Young and Elderly AdultsThe Journal of Infectious Diseases, 1996
- Influenza A Virus Vaccines Containing Purified Recombinant H3 Hemagglutinin Are Well Tolerated and Induce Protective Immune Responses in Healthy AdultsThe Journal of Infectious Diseases, 1995